Wuhan Wansheng Biotechnology: difference between revisions
Diff·revision 21 → 22·16:00, 14 May 2025
Difference between revision 21 and revision 22 of Wuhan Wansheng Biotechnology. 7 lines changed; the page grew by 332 bytes.
| Revision 21 — 18:31, 26 Apr 2025 TrialsTabitha (talk) attribute the capability claim to the organisation's own material 10,999 bytes +746 | Revision 22 — 16:00, 14 May 2025 RetatrutideRuben (talk) expand §Distribution and dispatch 11,331 bytes +332 | ||
|---|---|---|---|
| 75 | Material described here is labelled [[Research use only|for research use only]] and is '''not approved for human use''' in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them. | 75 | Material described here is labelled [[Research use only|for research use only]] and is '''not approved for human use''' in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them. |
| 76 | 76 | ||
| + | 77 | [https://wuhanwanshengbio.com/ Go to the WWB catalogue →] | |
| + | 78 | ||
| 77 | == Reception == | 79 | == Reception == |
| 78 | The PeptidePedia tally records 914 self-reported submissions to July 2026. Recurring themes are catalogue breadth and the sheer availability of independent testing data — more third-party reports have been associated with this organisation's material than with any other covered here, which is what makes its record unusually examinable.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 80 | The PeptidePedia tally records 914 self-reported submissions to July 2026. Recurring themes are catalogue breadth and the sheer availability of independent testing data — more third-party reports have been associated with this organisation's material than with any other covered here, which is what makes its record unusually examinable.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| ⋮ | ⋮ | ||
| 87 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> | 89 | <ref name="ruo">Research-use-only labelling practice; see [[Research use only]] for the legal and commercial function of the phrase.</ref> |
| 88 | 90 | ||
| + | 91 | == Further reading == | |
| + | 92 | * [[Project:Vendor notability]] — the criteria under which this article exists, and what supplier articles may not contain. | |
| + | 93 | * [[Project:Sourcing guidelines]] — how test reports and community tallies are cited on this wiki. | |
| + | 94 | ||
| 89 | == See also == | 95 | == See also == |
| 90 | * [[Certificate of analysis]] | 96 | * [[Certificate of analysis]] |
| ⋮ | ⋮ | ||
| 94 | * [[Research use only]] | 100 | * [[Research use only]] |
| 95 | * [[Peptide supply chain]] | 101 | * [[Peptide supply chain]] |
| + | 102 | * [[Blind sampling]] | |
| 96 | 103 | ||
| 97 | {{DEFAULTSORT:Wuhan Wansheng Biotechnology}} | 104 | {{DEFAULTSORT:Wuhan Wansheng Biotechnology}} |